Skip to main content
Premium Trial:

Request an Annual Quote

Euformatics Receives CE Mark for OmnomicsNGS Clinical Decision Support Tool

NEW YORK (GenomeWeb) – Finnish bioinformatics firm Euformatics announced today that it has received CE Marking for omnomicsNGS, a tool that helps labs interpret genetic variants and make clinical decisions.

The tool can help determine whether individual variants can have an effect on a patient's disease risk, or response to drugs or treatment, the company said. It performs variant annotation using the most recent disease-specific translational research and user-provided knowledge.

Euformatics launched the omnomicsQ, a management system for NGS workflows, in April 2015. The system lets users lay out quality metrics, draw up plans that determine the standards that are needed for NGS projects, and define tests that determine if a project conforms to the quality specifications laid out in the quality management plan. It's also the only quality management software that allows diagnostic laboratories to follow CAP or EuroGentest guidelines, the company said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.